Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
This randomized phase I trial studies the side effects and best way to give vaccine therapy
together with basiliximab in treating patients with acute myeloid leukemia (AML) in complete
remission. Vaccines made from the WT1 peptide may help the body build an effective immune
response to kill cancer cells. Montanide ISA 51 VG and poly-ICLC may enhance this response.
Monoclonal antibodies, such as basiliximab, can block cancer growth in different ways. Some
block the ability of cancer to grow and spread. Others find cancer cells and help kill them
or carry cancer-killing substances to them. It is not yet known whether WT1 126-134 peptide
vaccine with Montanide ISA 51 VG is more effective than with poly-ICLC when given together
with basiliximab in treating AML